18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer
- 4 March 2020
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 34 (5) , 322-328
Abstract
Objectives Programmed cell death-ligand 1 (PD-L1) is expressed on tumor cells (TC) and tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the relationship between PD-L1 expression on TC/IC and 18F-FDG uptake in patients with surgically resected non-small cell lung cancer (NSCLC). Methods Total 362 NSCLC patients (297 adenocarcinoma and 65 squamous cell carcinoma) who underwent preoperative 18F-FDG-PET/CT imaging were analyzed retrospectively. Immunohistochemistry analysis was performed for PD-L1 expression on TC and IC in NSCLC specimens with 28–8 antibody. The cut-off value of 5% for defining PD-L1 positivity was determined according to previous trials. The association between PD-L1 expression and clinicopathological variables were analyzed, including age, gender, smoking status, tumor diameter, lymph node metastasis, stage and the maximum standardized uptake value (SUVmax). Results PD-L1 positive expression was 50.8% (184/362) in NSCLC patients. Its positive expression on TC and IC were 24.3% (88/362) and 42.5% (154/362), respectively. SUVmax was significantly higher in patients with PD-L1 positive expression on TC or IC than that with negative. Multivariate analysis demonstrated that PD-L1 expression were correlated with SUVmax. The best cut-off value of SUVmax for PD-L1 expression on TC/IC was 8.5 [area under the curve (AUC) = 0.607, 95% CI 0.549–0.665, P = 0.001, sensitivity 50.5% and specificity 71.4%] determined by ROC curve. Conclusion High SUVmax is linked to PD-L1 expression on TC and IC in our patients with surgically resected non-small cell lung cancer. 18F-FDG-PET/CT imaging may be used to predict the PD-L1 expression on TC and IC in NSCLC patients.Keywords
This publication has 27 references indexed in Scilit:
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patientsScientific Reports, 2016
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomasLaboratory Investigation, 2016
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgeryEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinomaHead & Neck, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current dataOral Oncology, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014